{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:39Z","timestamp":1777934739211,"version":"3.51.4"},"reference-count":6,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sacituzumab govitecan is approved for the treatment of triple-negative advanced\/metastatic breast cancer and hormone-receptor positive, HER2-negative advanced\/metastatic breast cancer. Clinical trials show favorable improvements in progression-free survival (PFS) and overall survival (OS). However, they report a large percentage of patients experiencing hypersensitivity reactions. It has been observed that use of sacituzumab govitecan at [redacted institution] may have a lower rate of hypersensitivity reactions than seen in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study aimed to determine the real-world data of PFS and OS of sacituzumab govitecan while evaluating the incidence and severity of hypersensitivity reactions. It was a retrospective, single-center, multi-site study conducted across [redacted], which included adult patients who received at least one dose of sacituzumab govitecan from April 1, 2020 to July 31, 2024 for an FDA-approved breast cancer indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 75 patients met the inclusion criteria for assessment. The median PFS was 2.8 months (95% CI, 0.0\u201314.4) and the median OS was 7.2 months (95% CI, 0.0\u201319.3). No hypersensitivity reactions were reported, hence reaction severity was not assessed nor associated with treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>This study demonstrated that PFS and OS may be shorter than estimated in clinical trials. However, baseline performance status and previous lines of therapy were not evaluated and thus may have impacted the results. Additionally, no hypersensitivity reactions were observed. From review of this data, the low risk of reactions helps justify future research to assess the necessity of certain premedications and\/or elimination of observation times.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261423836","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:35:16Z","timestamp":1771263316000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab govitecan in breast cancer patients \u2013 an evaluation of progression-free survival, overall survival, and hypersensitivity reactions in real-world patients"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2591-9175","authenticated-orcid":false,"given":"Kaitlyn","family":"Becker","sequence":"first","affiliation":[{"name":"Novant Health Forsyth Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Walczak","sequence":"additional","affiliation":[{"name":"Novant Health Presbyterian Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolly","family":"Patel","sequence":"additional","affiliation":[{"name":"Novant Health Presbyterian Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Trodelvy (sacituzumab govitecan-hziy) [prescribing information]","year":"2023","unstructured":"Trodelvy (sacituzumab govitecan-hziy) [prescribing information]. Foster City, CA: Gilead Sciences, Inc, 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_3_5_2","volume-title":"Micromedex solutions","author":"Sacituzumab govitecan-hziy","unstructured":"Sacituzumab govitecan-hziy. Micromedex solutions. Greenwood Village, CO: Truven Health Analytics, http:\/\/micromedex.com\/ (Updated 28 February 2024, accessed 26 August 2024)."},{"key":"e_1_3_3_6_2","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 4.2024) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (accessed 3 October 2024)."},{"key":"e_1_3_3_7_2","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5(11.pdf. (Published 27 November 2017 accessed 26 August 2024)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261423836","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:26Z","timestamp":1777689146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261423836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":6,"alternative-id":["10.1177\/10781552261423836"],"URL":"https:\/\/doi.org\/10.1177\/10781552261423836","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"10781552261423836"}}